Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Generation Bio Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Generation Bio şirketinin toplam hissedar öz sermayesi $115.4M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $265.3M ve $149.9M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$216.94m
Eşitlik	US$115.41m
Toplam yükümlülükler	US$149.86m
Toplam varlıklar	US$265.26m

Son finansal sağlık güncellemeleri

Recent updates

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

May 01

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Dec 07

Companies Like Generation Bio (NASDAQ:GBIO) Can Afford To Invest In Growth

Jul 11

We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely

Mar 11

Generation Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth Plans

Nov 19

We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely

Aug 05

Generation Bio GAAP EPS of -$0.66 misses by $0.04

Aug 04

Companies Like Generation Bio (NASDAQ:GBIO) Are In A Position To Invest In Growth

Apr 20

Generation Bio: High-Risk, Medium-To-Low-Reward

Dec 30

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Nov 11

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Jul 28

Here's Why We're Not Too Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn Situation

Mar 08

Trade Alert: The Independent Director Of Generation Bio Co. (NASDAQ:GBIO), Charles Rowland, Has Just Spent US$500k Buying 25% More Shares

Jan 14

Generation Bio's insiders on buying spree, stock +4%

Jan 13

Generation Bio prices equity offering at $24.50

Jan 07

Generation Bio files to offer 7.5M shares

Jan 04

Should You Take Comfort From Insider Transactions At Generation Bio Co. (NASDAQ:GBIO)?

Dec 27

Generation Bio EPS misses by $0.01

Nov 10

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: GBIO 'nin kısa vadeli varlıkları ( $223.3M ) kısa vadeli yükümlülüklerini ( $30.1M ) aşıyor.

Uzun Vadeli Yükümlülükler: GBIO şirketinin kısa vadeli varlıkları ( $223.3M ) uzun vadeli yükümlülüklerini ( $119.8M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: GBIO borçsuzdur.

Borcun Azaltılması: GBIO son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: GBIO şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: GBIO serbest nakit akışı her yıl % 7.2 2.8 yıl yetecek nakit akışına sahip olacaktır.

Generation Bio Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Companies Like Generation Bio (NASDAQ:GBIO) Can Afford To Invest In Growth

We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely

Generation Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely

Recent updates

Consensus revenue estimates increase by 38%, EPS downgraded

Generation Bio Co. has filed a Follow-on Equity Offering in the amount of $237 million.

Consensus revenue estimates increase by 29%, EPS downgraded

Generation Bio Co. Announces the Presentation of Preclinical Data on iqDNA and ctLNP Platforms At the ASGCT 27th Annual Meeting

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Generation Bio Co., Annual General Meeting, Jun 06, 2024

Insufficient new directors

Consensus revenue estimates increase by 101%

Price target decreased by 16% to US$7.25

New major risk - Revenue and earnings growth

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Independent Director recently bought US$478k worth of stock

Generation Bio Co. Announces Termination of Executives, Effective on January 28, 2024

Consensus revenue estimates increase by 51%

Price target decreased by 17% to US$9.00

Generation Bio Co. Announces Demonstration of Highly Selective T Cell Transduction in Vivo with Cell-Targeted Lnp Platform

New minor risk - Market cap size

Generation Bio Co. Announces Breakthrough in Its Non-Viral Genetic Medicine Platform with Novel "Immune-Quiet" Dna

Consensus revenue estimates increase by 270%

Consensus revenue estimates decrease by 41%, EPS upgraded

Price target decreased by 12% to US$11.42

New major risk - Share price stability

Companies Like Generation Bio (NASDAQ:GBIO) Can Afford To Invest In Growth

We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely

Price target decreased by 19% to US$13.00

Generation Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth Plans

Price target decreased to US$16.67

Insufficient new directors

Price target decreased to US$16.67

President exercised options and sold US$58k worth of stock

Generation Bio Co. Names Phillip Samayoa as Chief Strategy Officer

Independent Director recently bought US$127k worth of stock

We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely

Generation Bio GAAP EPS of -$0.66 misses by $0.04

Insufficient new directors

Generation Bio Co. Appoints Dannielle Appelhans as Class III Director and Member of N&G Committee

Generation Bio Co.(NasdaqGS:GBIO) dropped from Russell 2000 Growth Index

Generation Bio Co. Announces Update to its Good Manufacturing Process Manufacturing Strategy

Price target decreased to US$20.40

Insufficient new directors

Companies Like Generation Bio (NASDAQ:GBIO) Are In A Position To Invest In Growth

Price target decreased to US$20.40

Generation Bio Co. Appoints Antoinette Paone as Chief Operating Officer

Generation Bio: High-Risk, Medium-To-Low-Reward

Generation Bio Provides Update on Preclinical Studies for Hemophilia A Program

Price target decreased to US$33.40

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Insufficient new directors

Chief Scientific Officer exercised options and sold US$64k worth of stock

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Generation Bio Announces Plan to Scale Next-Generation Rapid Enzymatic Manufacturing Process Across Portfolio and Provides Pipeline Update

Chief Medical Officer notifies of intention to sell stock

Chief Scientific Officer exercised options and sold US$136k worth of stock

Chief Scientific Officer notifies of intention to sell stock

Chief Scientific Officer exercised options and sold US$269k worth of stock

Chief Development Officer notifies of intention to sell stock

Chief Scientific Officer exercised options and sold US$96k worth of stock

Chief Medical Officer exercised options and sold US$351k worth of stock

Here's Why We're Not Too Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn Situation

President notifies of intention to sell stock

Generation Bio Co. Appoints Ron Cooper to its Board of Directors, Effective March 1, 2021

Co-Founder & COO Mark Angelino has left the company

Chief Development Officer exercised options and sold US$71k worth of stock

Chief Medical Officer notifies of intention to sell stock

Trade Alert: The Independent Director Of Generation Bio Co. (NASDAQ:GBIO), Charles Rowland, Has Just Spent US$500k Buying 25% More Shares

Generation Bio's insiders on buying spree, stock +4%

Generation Bio prices equity offering at $24.50

Generation Bio Announces Two Non-Viral Gene Therapy Achievements: Target Levels of Factor VIII Expression in Hemophilia A Mice and Translation of Expression from Mice to Non-Human Primates

Generation Bio files to offer 7.5M shares